Try our Advanced Search for more refined results
Stamoulis & Weinblatt
-
Motion | Filed: April 26, 2024 | Entered: April 26, 2024 Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc.
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Stipulation to EXTEND Time
STIPULATION TO EXTEND TIME to serve rebuttal expert reports to May 24, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis)
-
Motion | Filed: April 26, 2024 | Entered: April 26, 2024 In Re: Ozempic (Semaglutide) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Stipulation to EXTEND Time
STIPULATION TO EXTEND TIME to serve rebuttal expert reports to May 24, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis)
-
Order | Filed: April 26, 2024 | Entered: April 26, 2024 Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Order ~Util - Add and Terminate Parties
SO ORDERED Granting (D.I. 180 in 22-cv-01395-RGA; D.I. 1339 in 20-md-02930-RGA; D.I. 68 in 23-cv-401-RGA) Stipulation and Proposed Order Joining Gerbera Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 4/26/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login